Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +1.65% 30.75p 30.00p 31.50p 30.75p 30.25p 30.25p 25,000.00 14:10:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.6 -2.5 - 28.09

Synairgen Share Discussion Threads

Showing 576 to 599 of 600 messages
Chat Pages: 24  23  22  21  20  19  18  17  16  15  14  13  Older
DateSubjectAuthorDiscuss
22/3/2017
14:57
Share price nearly back to where it was pre AZN announcement.....
wookie77
13/3/2017
22:37
Herewith a few notes from my phone conversation with RM of Friday afternoon (the Q&As are paraphrased, they are not verbatim): Q: Has there been some slippage on the timeline for an update on the Interferon study with Astra Zeneca? A: We may have previously stated Q1, we are now stating H1 and we are confident about that, although the timings are ultimately down to Astra Zeneca. Q: Can you tell us anything more about the lead compound, such as likely dose, PK properties, chemical structure? A: Most of that is confidential, it doesn’t have a name or number yet, it is a small molecule, it is not a peptide, preclinical data suggests it should be suitable for oral administration. Tox is ongoing, we will update when the necessary tox program to support a Phase I study is complete (later this year). Q: You have mentioned other indications for the LOXL2 program in addition to IPF such as liver, kidney and cardiac fibrosis. What about other more common fibrotic conditions such as Peyronie's disease and Dupuytren's contracture where there is a real unmet clinical need? These could be massive markets. A: Dupuytren's contracture has been mentioned a few times in meetings, but not Peyronie’s disease, we will make enquiries. * Dupuytren's contracture: https://en.wikipedia.org/wiki/Dupuytren%27s_contracture * Peyronie’s disease: https://en.wikipedia.org/wiki/Peyronie%27s_disease Q: Are Pharmaxis likely to develop just one molecule for all LOXL2 indications, or could it be multiple molecules? There may be commercial advantages for them to have different molecules for different indications as they could then have multiple partners, but this could mean SNG might be shut out of royalties for the additional indications. A: Our agreement covers all exploratory compounds in the LOXL2 program, so there is likely to be only one lead molecule. Pharmaxis may develop molecules which have some LOX2 activity but are predominantly specific for LOX, LOXL1, LOXL3 or LOXL4, such compounds would not necessarily be covered by the Synairgen agreement. LOXL2 is the main target for fibrosis of soft organs, but for structural tissue fibrosis the enzymes responsible may be other types of LOXL or LOX
timbo003
13/3/2017
17:59
Latest RNS Today.. Woodford has increased his holding by 125000 shares to 21,091,651..He now control's 23% of SNG share capital.
rosejs2
11/3/2017
15:21
Thanks Timbo - oddly enough I added 50% to my PXS holding week before last - whole fibrosis space there much undervalued IMV - CEO bought shares there 1st week December at around the current 28c price though I'd be surprised if it stayed there Monday..
ohisay
10/3/2017
23:18
That was really good news today: Efficacy demonstrated in several different preclinical models, the lead candidate is bioavailable following oral administration (in animal models) and tox looking good so far. There's a new interview with Richard Marsden here: http://www.proactiveinvestors.co.uk/companies/stocktube/7083/synairgen-s-chief-hails-exciting-ipf-data-from-loxl2-inhibitor-programme-7083.html I also had a chance to have a quick phone chat with RM late this afternoon which helped fill in a few gaps, I will write up a few notes on that and post them here sometime over the weekend.
timbo003
17/2/2017
09:35
Steve - If you want to see a real ramper at work look at these posts (especially on the 19th). http://uk.advfn.com/forum/search?q=whites123&index=posts&post_poster=on&offset=0 He's done exactly the same thing on iii under a different name - disorder. Give him a suitably wide berth in future.
ohisay
16/2/2017
11:51
hahahahaha, couldn't help yourself but get a wee ramp in there are end, you're an addict, lol!!....but also the upside reward is hugeRAAAAAMMMMMPITY RAMP, RAMP RAMP!!
nakedsteve
16/2/2017
11:33
Ahhhh poor Steve i tend to find people who bang on about ramping have been the victim of it in the past. How much pocket money did you loose Steve? :D LOL BTW 10/20 times current valution on succesful AZ trial is not a ramp and if you cant see that valuation possible then you should not be here. this i backed up by broker notes as well. DOWNSIDE is they run out of money and the trial busts out...... there you go a balanced DERAMP just for you! Im well aware of the risks but also the upside reward is huge.
wookie77
16/2/2017
11:12
Wookie the winker and his blatant ramping...
nakedsteve
16/2/2017
11:11
more to this I think never seen this type of action before AZ must have something positive to say on the trial
nakedsteve
16/2/2017
11:11
INtersting and thanks ill take a look. We are still only valued at £19m here. I can genuinely see this at 10 or even 20 times that valuation on our potential. Not overnight of course but should the stars align as everyone hopes.
nakedsteve
16/2/2017
11:11
This is more than stakebuilding IMO.
nakedsteve
16/2/2017
11:10
no holdings Rns. Someone's got wind of something this is relentless not how an institutional buy order is filled!
nakedsteve
16/2/2017
11:10
How about your previous 10 comments before that?
nakedsteve
16/2/2017
09:57
Wookie77 15 Feb '17 - 12:32 - 500 of 511 0 0 Edit I would agree but whats driving it. I took 50k off the table yesterday but still holding 100k which will have to be prized out of my dead cold hands. But hoping ill be able to buy the 50k back cheaper. Im not so sure though. I think much more of a rise and the company will have to make an announcement. "no reason" or trial news
wookie77
16/2/2017
09:56
oh and please explain why im a ramper?
wookie77
16/2/2017
09:56
YEs im here. thanks
wookie77
16/2/2017
09:49
No sign of Wookie the Ramper? now there's a surprise......
nakedsteve
16/2/2017
09:13
TIIIIIMMMBBBBEEEERRRR....
nakedsteve
16/2/2017
07:17
Thanks for the Pharmaxis link chaps http://www.pharmaxis.com.au/assets/Documents/pdf/02017/ASX/2017-02-13-PXS-Investor-Presentation-Update.pdf There are several useful slides in that deck, especially those that show the competitive activity for LOX2 (and LOX2 inhibitor indications)
timbo003
16/2/2017
06:37
The company, meanwhile, isn’t short of a bob or two. The last results showed it had around £7.7mln in the bank, enough for over three years at the current burn rate. And, rather refreshingly for a man working in the cash-hungry drug development industry, CEO Marsden said Synairgen has enough funds to meet its current needs. “We are going flat out. More money wouldn’t make us go faster,” he added.
whites123
16/2/2017
01:15
Rose SJ - the last few years burn rate isn't typical of what it needs to do this year as part of the dvpt of its phase 1 LOXL2 collaboration with PXS (which I hold incidentally ). They've probably got just over £4m cash at the moment which isn't going to be enough to comfortably fund that through H2 .As they said in their interims the fall in sterling hasn't helped with their cash outflows. Of course they were due to get 10m$ from AZN on a successful Phase 2 IFB trial but that's up in the air after AZN stopped it in October so we wait for probable news in about a months time. PXS is a great company IMV and that updated presentation while not saying much new on LOXL2 since last year shows that the whole fibrosis area which they are in isn't a bad place to be at all. With the extra cash due in from Boehringer shortly the implied EV doesnt look up to speed to me so consider buying a few of those I'd say.
ohisay
15/2/2017
17:23
More details on LOXL2 released in Pharmaxis presentation dated 13th Feb 2017: hxxp://www.pharmaxis.com.au/assets/Documents/pdf/02017/ASX/2017-02-13-PXS-Investor-Presentation-Update.pdf
b1lbo
15/2/2017
16:45
From Proactive Investor 5th April 2016 (Investment Overview) Extract The company, meanwhile, isn’t short of a bob or two. The last results showed it had around £7.7mln in the bank, enough for over three years at the current burn rate. And, rather refreshingly for a man working in the cash-hungry drug development industry, CEO Marsden said Synairgen has enough funds to meet its current needs. “We are going flat out. More money wouldn’t make us go faster,” he added.
rosejs2
Chat Pages: 24  23  22  21  20  19  18  17  16  15  14  13  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170326 05:28:54